98%
921
2 minutes
20
Objectives: In the EMergency department-initiated BuprenorphinE for opioid use Disorder (EMBED) trial, a clinical decision support (CDS) tool had no effect on rates of buprenorphine initiation in emergency department (ED) patients with opioid use disorder. The Agency for Healthcare Research and Quality (AHRQ) recently released a CDS Performance Measure Inventory to guide data-driven CDS development and evaluation. Through partner co-design, we tailored AHRQ inventory measures to evaluate EMBED CDS performance and drive improvements.
Methods: Relevant AHRQ inventory measures were selected and adapted using a partner co-design approach grounded in consensus methodology, with three iterative, multidisciplinary partner working group sessions involving stakeholders from various roles and institutions; meetings were followed by post-meeting surveys. The co-design process was divided into conceptualization, specification, and evaluation phases building on the Centers for Medicare and Medicaid Services' measure life cycle framework. Final measures were evaluated in 3 EDs in a single health system from 1/1/2023-12/31/2024.
Results: The partner working group included 25 members. During conceptualization, 13 initial candidate metrics were narrowed to 6 priority categories. These were further specified and validated as the following measures, presented with preliminary values based on use of the current (i.e., pre-optimization) EMBED CDS: eligible encounters with CDS engagement, 5.0% (95% CI: 4.3-5.8%); teamwork on ED initiation of buprenorphine, 39.9% (32.5%-47.3%); proportion of eligible users who used EMBED, 58.3% (50.9%-65.8%); time spent on EMBED 29.0 seconds (20.4-37.7 seconds); proportion of buprenorphine orders placed through EMBED, 6.5% (3.4%-9.6%); and task completion, 13.8% (8.9%-18.7%) for buprenorphine order/prescription.
Conclusions: A measurement science framework informed by partner co-design was a feasible approach to develop measures to guide CDS improvement. Subsequent research could adapt this approach to evaluate other CDS applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-2595-0317 | DOI Listing |
J Exp Anal Behav
September 2025
Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, USA.
Polydrug abuse is the persistent self-administration of more than one reinforcing drug. The present study provided rhesus monkeys concurrent access to two drugs: 8% alcohol and solutions of either cocaine or methadone. The liquids were available under concurrent nonindependent fixed-ratio (FR) schedules across increasing and then decreasing ratio sizes.
View Article and Find Full Text PDFPerm J
September 2025
Department of Pharmacy, Kaiser Permanente Georgia, Atlanta, GA, USA.
Background: Opioids are highly effective for pain management but carry risks. Naloxone quickly reverses opioid overdoses by blocking opioid receptors in the brain. Despite its effectiveness, naloxone remains underutilized.
View Article and Find Full Text PDFAddict Sci Clin Pract
September 2025
Department of Psychiatry, Brigham and Women's Hospital, 60 Fenwood Rd, Boston, MA, 02115, USA.
Arch Psychiatr Nurs
October 2025
University of Pittsburgh School of Nursing, Department of Health and Community Systems, 3500 Victoria St. Pittsburgh, PA 15213, United States of America. Electronic address:
Background: Women veterans are at risk for substance use and substance use disorders, although there remains limited data on substance use in women veterans.
Methods: A secondary analysis of data from the National Survey on Drug Use and Health from 2015 to 2019 and 2021 was conducted to compare women veterans with women non-veterans and men veterans on substance-related outcomes, including lifetime substance use, frequency of past 30-day substance use, and past-year substance use disorders for cannabis, opioids, and stimulants.
Results: From 2015 to 2019, women veterans were about 53 % and 24 % more likely to have used cannabis in their lifetime compared to women non-veterans and men veterans, respectively.
Am J Prev Med
September 2025
Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA.
Introduction: Opioid-related deaths among perinatal populations have increased sharply in the United States. Whether the recent ascendence of illicit fentanyl and other synthetic opioids in the drug supply translates to increasing prenatal opioid use disorder (OUD) remains unknown. This study tested whether California's comparatively late fentanyl influx, in 2019, was associated with a subsequent increase in OUD among pregnant people.
View Article and Find Full Text PDF